Loading
Elevance Health, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BOUDREAUX GAIL, was filed 17 Jul 2026.
Insider Decl.
892
Thresholds
n/a
Buy Volume
€7M
12 ops. · all time
Sell Volume
€264M
270 ops. · all time
Who traded when
BuySaleMark Kaye14 sales
Gail Boudreaux5 buys
Kendrick Charles Morgan JR2 sales
Ronald W. Penczek2 sales
Collis Steven H1 buy
DeVore Susan D.1 buy
+2 other insiders
Since the insiders bought
- +17.0%Entry US$382.23 · Close 22 Oct 2026 US$447.18
- +17.0%Entry US$382.23 · Close 22 Oct 2026 US$447.18
- +48.0%Entry US$280.74 · Close at T+90 US$415.53
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Elevance Health, Inc. Buy (bullish), based on 21 analysts. Average price target: US$456.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 14,102 of 26,250 companies
49.3
score / 100
Value54
Quality45
FCF yld3.4%
Earn yld6.0%
EV/EBITDA15.2x
ROE11%
Gross mgn·
Net mgn2.8%
Debt/EBITDA3.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$434.13
Analyst consensus
21 analystsBuy
US$395.00Target US$456.00(+5%)US$508.00
Income statement
RevenueUS$199.1B
EBITDAUS$8.3B4% margin
Net incomeUS$5.7B2.5% margin
Valuation
PER (trailing)18.4x
PER (forward)14.6x
P/Book2.1x
Beta0.71
Balance sheet & cash
Market capUS$94.1B
Total debtUS$32B
Free Cash FlowUS$3.2B
Debt / Equity69%
Profitability & ownership
ROE11.1%
ROA3.8%
% insiders0.2%
% institutions94.1%
Last declaration on 23 October 2026
Declarations892 total
400 shares@ US$434.00Common StockSEC:0001748691-26-000008:0
321 shares@ US$435.25Common StockSEC:0001748691-26-000008:1
1,660 shares@ US$436.20Common StockSEC:0001748691-26-000008:2
560 shares@ US$437.07Common StockSEC:0001748691-26-000008:3
240 shares@ US$438.22Common StockSEC:0001748691-26-000008:4
1,160 shares@ US$439.25Common StockSEC:0001748691-26-000008:5
1,720 shares@ US$440.44Common StockSEC:0001748691-26-000008:6
2,343 shares@ US$441.34Common StockSEC:0001748691-26-000008:7
480 shares@ US$442.61Common StockSEC:0001748691-26-000008:8
440 shares@ US$443.81Common StockSEC:0001748691-26-000008:9
160 shares@ US$444.85Common StockSEC:0001748691-26-000008:10
827 shares@ US$446.05Common StockSEC:0001748691-26-000008:11
273 shares@ US$447.19Common StockSEC:0001748691-26-000008:12
10,584 shares@ US$440.1340.0049% mcap100.0% of flowCommonSEC144:0001950047-26-010359
4,161 shares@ US$386.430.0019% mcap26.3% of flowCommon StockSEC:0001748691-26-000005:0
2,627 shares0Common StockSEC:0001748691-26-000005:1
144 shares@ US$405.840.0001% mcap36.8% of flowCommon StockSEC:0002084547-26-000009:0
94 shares@ US$405.840.0000% mcap19.8% of flowCommon StockSEC:0002084548-26-000005:0
255 shares@ US$414.780.0001% mcap54.9% of flowCommon StockSEC:0002084548-26-000005:1
680 shares@ US$366.410.0003% mcap0.7% of flowCommon StockSEC:0001287920-26-000006:0
Canonical exit: 15 Oct 2026 (T+90)
2,045 shares@ US$368.250.0009% mcap2.0% of flowCommon StockSEC:0001287920-26-000006:1
Canonical exit: 15 Oct 2026 (T+90)
1,000 shares@ US$366.050.0004% mcap30.9% of flowCommon StockSEC:0001192045-26-000004:0
Canonical exit: 15 Oct 2026 (T+90)
1,500 shares@ US$419.910.0007% mcap100.0% of flowCommonSEC144:0001959173-26-005153
369 shares@ US$403.165.7% of flowCommon StockSEC:0001659075-26-000006:0
369 shares@ US$403.16350.0002% mcap100.0% of flowCommonSEC144:0001950047-26-006048
25 of 892 declarations
About Elevance Health, Inc.
On July 17, 2026, 2 Elevance Health, Inc. insiders bought on the same day for EUR 1,195,466. Purchases are rare in this record: 12 worth EUR 7,025,731 (median EUR 452,047), or 4% of open-market trades, against 257 sales worth EUR 259,783,217 (median EUR 435,759). Gail Boudreaux (President and CEO) bought for EUR 1,339,504 on January 30, 2020 and EUR 1,264,610 on July 18, 2025; Steven H. Collis (Director) for EUR 747,292 on March 5, 2026.
The three largest sales are Brian T. Griffin's (EVP & CEO, IngenioRx), EUR 10,196,434 on May 3, 2018, Gail Boudreaux's, EUR 9,547,444 on July 22, 2024, and Peter D. Haytaian's (EVP & President, Commercial), EUR 7,876,187 on March 22, 2021.
Read moreShow less
The 878 filings from 40 insiders were published from January 29, 2016 to October 6, 2026. 2018 is the busiest year (124). Over the last twelve months: 60 filings, 4 purchases, 3 sales. The median delay is 2 days.
For 12 purchases with a stored 90-day result, the median is 12.8% and 92% are positive: stored past results, not a forecast. This US healthcare and pharma company is worth USD 93.3 billion; insiders hold 0.2% of the capital.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
